Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2356 to 2370 of 7685 results

  1. Palopegteriparatide for treating chronic hypoparathyroidism [ID6380]

    In development [GID-TA11454] Expected publication date: 16 July 2025

  2. Slide sheets for repositioning or moving a person on or from a bed: Late Stage Assessment

    In development [GID-HTE10051] Expected publication date: 28 May 2025

  3. Tiratricol for treating Allan–Herndon–Dudley syndrome ID6217

    Awaiting development [GID-TA11192] Expected publication date: TBC

  4. Gambling-related harms: identification, assessment and management

    In development [GID-NG10210] Expected publication date: TBC

  5. Belantamab mafodotin with bortezomib and dexamethasone for treating relapsed or refractory multiple myeloma after 1 or more treatments ID6212

    In development [GID-TA11203] Expected publication date: 05 March 2025

  6. PICO negative pressure wound dressings for closed surgical incisions (MTG43)

    Evidence-based recommendations on PICO negative pressure wound dressings for closed surgical incisions.

  7. Endocuff Vision for assisting visualisation during colonoscopy (MTG45)

    Evidence-based recommendations on Endocuff Vision for assisting visualisation during colonoscopy.

  8. gammaCore for cluster headache (MTG46)

    Evidence-based recommendations on gammaCore for cluster headache.

  9. Senza spinal cord stimulation system for delivering HF10 therapy to treat chronic neuropathic pain (MTG41)

    Evidence-based recommendations on the Senza spinal cord stimulation system for delivering HF10 therapy to treat chronic neuropathic pain.

  10. UrgoStart for treating diabetic foot ulcers and leg ulcers (MTG42)

    Evidence-based recommendations on UrgoStart for treating diabetic foot ulcers and leg ulcers.

  11. Tegaderm CHG securement dressing for vascular access sites in critically ill adults (MTG25)

    Evidence-based recommendations on The 3M Tegaderm CHG IV securement dressing for central venous and arterial catheter insertion sites.

  12. Idebenone for treating visual impairment in Leber's hereditary optic neuropathy in people 12 years and over [ID547]

    In development [GID-TA11288] Expected publication date: 23 April 2025

  13. Acalabrutinib with bendamustine and rituximab for untreated mantle cell lymphoma [ID6155]

    In development [GID-TA11091] Expected publication date: 20 August 2025

  14. Pembrolizumab with chemoradiotherapy for untreated unresectable oesophageal cancer [ID6270]

    Awaiting development [GID-TA11303] Expected publication date: TBC

  15. Atezolizumab for adjuvant treatment of resected non-small-cell lung cancer (MA review of TA823) [ID6324]

    In development [GID-TA11616] Expected publication date: 23 July 2025